07:00 , Jul 19, 2012 |  BC Innovations  |  Targets & Mechanisms

OutFOXing tumors

A Mount Sinai School of Medicine and Case Western Reserve University team has found a new use for the dopamine receptor antagonist trifluoperazine: restoring the sensitivity of tumors to epidermal growth factor receptor inhibitors. 1...
07:00 , Sep 4, 2006 |  BC Week In Review  |  Company News

Gardent Pharmaceuticals Inc., Symbollon, Switch Pharma deal

SYMBA and GRDP mutually terminated a marketing agreement for SYMBA's IoGen molecular iodine to treat pain and tenderness associated with fibrocystic breast disease (see BioCentury, April 18, 2005). GRDP, formerly Bioaccelerate Holdings Inc. , was...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Clinical News

RP101: Phase II start

By early next year, AVTO will begin a Phase II trial comparing 750 mg daily of RP101 plus gemcitabine to gemcitabine plus placebo. Avantogen Oncology Inc. (AVTO), Los Angeles, Calif.   Bioaccelerate Holdings Inc. (BACL),...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Clinical News

RP101: Interim Phase I data

Interim data from an open-label Phase I trial in 22 patients showed that RP101 plus gemcitabine led to survival rates of 68% and 39% at 6 and 12 months, respectively. The estimated median survival was...
07:00 , Aug 7, 2006 |  BC Week In Review  |  Company News

ArQule management update

ArQule Inc. (ARQL), Woburn, Mass.   Business: Cancer   Hired: Nigel Rulewski as CMO, formerly SVP of Bioaccelerate Holdings Inc. , now Gardant Pharmaceuticals Inc.  ...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Clinical News

RP101: Interim Phase II data

Interim data from an ongoing, 8-month, double-blind, placebo-controlled, German Phase II trial in 22 patients with metastatic pancreatic cancer showed that after 6 months 41% of patients were still alive, 23% had died and 36%...
07:00 , Apr 3, 2006 |  BC Week In Review  |  Company News

CuraGen management update

CuraGen Corp. (CRGN), Branford, Conn.   Business: Cancer, Inflammation, Endocrine   Hired: Frank Armstrong as president and CEO, formerly CEO of Bioaccelerate Holdings Inc.  ...
02:25 , Mar 31, 2006 |  BC Extra  |  Company News

CuraGen names Armstrong CEO

Cancer, inflammation and endocrine company CRGN hired Frank Armstrong as president and CEO. Armstrong, a CRGN director, previously was CEO of Bioaccelerate (BACL). CRGN also appointed Robert Patricelli, a director, as chairman. Patricelli is CEO...
07:00 , Sep 26, 2005 |  BC Week In Review  |  Clinical News

RP101: Additional Phase I/II data

Additional data from a previously reported open-label, German Phase I/II trial in 13 patients showed that 10 of the 13 patients taking 500 mg daily RP101 plus gemcitabine/cisplatin survived at least 1 year. The median...
07:00 , Jun 27, 2005 |  BC Week In Review  |  Company News

CuraGen board of directors update

CuraGen Corp. (CRGN), New Haven, Conn.   Business: Cancer, Inflammation, Endocrine   Appointed: Michael Astrue, former president and CEO of Transkaryotic Therapies Inc.; and Frank Armstrong, CEO of Bioaccelerate Inc.  ...